Differences in the Immune Response of the Nonmetastatic Axillary Lymph Nodes between Triple-Negative and Luminal A Breast Cancer Surrogate Subtypes

Identifier:  imarina:9162276

Handle: https://hdl.handle.net/20.500.11797/imarina9162276

Authors:  Lopez, Carlos; Gibert-Ramos, Albert; Bosch, Ramon; Korzynska, Anna; Garcia-Rojo, Marcial; Bueno, Gloria; Francesc Garcia-Fontgivell, Joan; Martinez Gonzalez, Salome; Fontoura, Laia; Gras Navarro, Andrea; Sauras Colon, Esther; Casanova Ribes, Julia; Roszkowiak, Lukasz; Roso, Albert; Berenguer, Marta; Llobera, Montserrat; Baucells, Jordi; Lejeune, Marylene

Abstract:
© 2021 American Society for Investigative Pathology Breast cancer (BC) comprises four immunohistochemical surrogate subtypes of which triple-negative breast cancer (TNBC) has the highest risk of mortality. Axillary lymph nodes (ALNs) are the regions where BC cells first establish before distant metastasis, and the presence of tumor cells in the ALN causes an immune tolerance profile that contrasts with that of the nonmetastatic ALN (ALN−). However, few studies have compared the immune components of the ALNs− in BC subtypes. The present study aimed to determine whether differences between immune populations in the primary tumor and ALNs− were associated with the luminal A or TNBC subtype. We evaluated a retrospective cohort of 144 patients using paraffin-embedded biopsies. The TNBC samples tended to have a higher histologic grade and proliferation index and had higher levels of immune markers compared with luminal A in primary tumors and ALNs−. Two methods for validating the multivariate analysis found that histologic grade, intratumoral S100 dendritic cells, and CD8 T lymphocytes and CD57 natural killer cells in the ALNs− were factors associated with TNBC, whereas CD83 dendritic cells in the ALNs− were associated with the luminal A subtype. In conclusion, we found that intratumoral regions and ALNs− of TNBC contained higher concentrations of markers related to immune tolerance than luminal A. This finding partially explains the worse prognosis of patients with TNBC.